Categories Earnings, Industrials
GE’s stock soars around 15% on news of Biopharma business sale to Danaher
General Electric’s (GE) stock jumped around 15% in premarket hours on Monday after the company announced the sale of its BioPharma business to Danaher Corporation (DHR) for $21.4 billion. Danaher is expected to pay $21 billion in cash as well as assume certain pension liabilities from GE.
The transaction is expected to close in the fourth quarter of 2019. GE plans to use the proceeds from the sale to reduce leverage and strengthen its balance sheet.
GE’s Chairman and CEO H. Lawrence Culp, Jr. said, “A more focused portfolio is the right structure for GE, and we have many options for maximizing shareholder value along the way.”
GE’s BioPharma business will be included within Danaher’s Life Sciences segment as a standalone entity. Danaher anticipates this business will deliver revenues of about $3.2 billion in 2019, with around 75% of these revenues considered recurring.
Danaher plans to finance the deal through cash on hand, issuance of debt or credit facilities as well as around $3 billion of proceeds from an equity offering. The company expects the acquisition to reduce GAAP EPS by approx. $1.15 to $1.20 but be accretive to non-GAAP EPS by approx. $0.45 to $0.50 in the first full year post acquisition.
The BioPharma business, which is part of the GE Life Sciences division, delivered revenues of around $3 billion in 2018. The company’s Pharmaceutical Diagnostics business, also a part of GE Life Sciences, will remain within the GE Healthcare portfolio. The GE Healthcare business, excluding BioPharma, generated about $17 billion of revenue with mid-teens operating profit margins last year.
Danaher’s stock gained 8.8% in premarket hours.
Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips.
Most Popular
Earnings Preview: Accenture (ACN) likely had a strong start to fiscal 2025
For Accenture plc. (NYSE: ACN), 2024 was a fruitful year marked by positive financial performance. The professional service firm effectively navigated a challenging market environment leveraging its agile business model
Signet Jewelers (SIG): Fashion remains a strong point for the jewelery retailer
Shares of Signet Jewelers Limited (NYSE: SIG) were down over 3% on Tuesday. The stock has dropped 12% over the past three months. The company faced challenges in the third
Pfizer (PFE) reaffirms FY24 forecast; provides FY25 guidance
Pharmaceutical company Pfizer Inc. (NYSE: PFE) Tuesday reaffirmed its financial outlook for fiscal 2024 and provided guidance for fiscal 2025. The company said it achieved the goal of $4 bln
Comments